Gene Therapy for Pleural Malignancies

Completed · Phase 1

Conditions studied: Pleural Mesothelioma, Metastatic Pleural Effusions

In brief

This Phase I study will evaluate the safety of two doses of BG00001 at different doses and intervals. Eligible subjects will have: * malignant pleural mesothelioma, or * pleural effusions who have progressed through at least one prior therapy or have refused therapy BG00001 is given twice through a catheter in the pleural space.

Key facts

Study ID
NCT00299962
Run by
University of Pennsylvania
People needed
17
Starts
2006-03-01
Expected to finish
2009-10-01
Last updated by the study team
2020-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.